bi213 m195
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2000 (NCT00014495)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Myeloid cell surface antigen CD33INHIBITOR
CD33 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 213-bismuth
Oral
No
Parenteral
No
Topical
No
Also known as
- bi213 m195
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00014495 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2000 | Cornell University, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2000 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2000 |
2 organizations
Page 1 / 1